Search company, investor...

Aimisen

ammulifetech.com

Founded Year

2015

Stage

Series C | Alive

Total Raised

$17.46M

Last Raised

$15.25M | 7 mos ago

About Aimisen

Aimisen specializes in the development, registration, production, sales, and testing of global non-invasive screening products for malignant tumors.

Headquarters Location

Building B10, Hi-Tech Medical Equipment Park, No. 818 Gaoxin Avenue, East Lake High-tech Development Zone

Wuhan, Hubei, 430200,

China

+86 027-87053628

Missing: Aimisen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aimisen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aimisen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aimisen is included in 3 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

M

Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Aimisen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aimisen Rank

Aimisen Frequently Asked Questions (FAQ)

  • When was Aimisen founded?

    Aimisen was founded in 2015.

  • Where is Aimisen's headquarters?

    Aimisen's headquarters is located at Building B10, Hi-Tech Medical Equipment Park, No. 818 Gaoxin Avenue, East Lake High-tech Development Zone, Wuhan.

  • What is Aimisen's latest funding round?

    Aimisen's latest funding round is Series C.

  • How much did Aimisen raise?

    Aimisen raised a total of $17.46M.

  • Who are the investors of Aimisen?

    Investors of Aimisen include CCB International, Wuhan Hi-Tech, Sanya Xuanpan, Hybribio Biotech, Changjiang Securities and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.